Current:Home > StocksEli Lilly cuts the price of insulin, capping drug at $35 per month out-of-pocket -AssetVision
Eli Lilly cuts the price of insulin, capping drug at $35 per month out-of-pocket
View
Date:2025-04-12 12:09:08
Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions.
The moves announced Wednesday promise critical relief to some people with diabetes who can face annual costs of more than $1,000 for insulin they need in order to live. Lilly's changes also come as lawmakers and patient advocates pressure drugmakers to do something about soaring prices.
Lilly said it will cut the list price for its most commonly prescribed insulin, Humalog, and for another insulin, Humulin, by 70% in the fourth quarter, which starts in October. The drugmaker didn't detail what the new prices would be.
List prices are what a drugmaker initially sets for a product and what people who have no insurance or plans with high deductibles are sometimes stuck paying.
Patient advocates have long called for insulin price cuts to help uninsured people who would not be affected by price caps tied to insurance coverage.
Lilly's planned cuts "could actually provide some substantial rice relief," said Stacie Dusetzina, a health policy professor at Vanderbilt University who studies drug costs.
She noted that the moves likely won't affect Lilly much financially because the insulins are older and some already face competition.
"It makes it easier for Lilly to go ahead and make these changes," she said.
Lilly also said Wednesday that it will cut the price of its authorized generic version of Humalog to $25 a vial starting in May.
The cost of a prescription for generic Humalog ranges between $44 and close to $100 on the website GoodRx.
Lilly also is launching in April a biosimilar insulin to compete with Sanofi's Lantus.
Lilly CEO David Ricks said in a statement that it will take time for insurers and the pharmacy system to implement its price cuts, so the drugmaker will immediately cap monthly out-of-pocket costs at $35 for people who are not covered by Medicare's prescription drug program.
The drugmaker said the cap applies to people with commercial coverage and at most retail pharmacies.
Lilly said people without insurance can find savings cards to receive insulin for the same amount at its InsulinAffordability.com website.
The federal government in January started applying that cap to patients with coverage through its Medicare program for people age 65 and older or those who have certain disabilities or illnesses.
American Diabetes Association CEO Chuck Henderson said in a statement he applauded the steps Lilly was taking and called for other insulin makers to also cap patient costs.
Aside from Eli Lilly and the French drugmaker Sanofi, other insulin makers include the Danish pharmaceutical company Novo Nordisk.
Neither company immediately responded to a request for comment Wednesday morning from The Associated Press.
Insulin is made by the pancreas and used by the body to convert food into energy. People who have diabetes don't produce enough insulin.
People with Type 1 diabetes must take insulin every day to survive. More than 8 million Americans use insulin, according to the American Diabetes Association.
Research has shown that prices for insulin have more than tripled in the last two decades, and pressure is growing on drugmakers to help patients.
President Joe Biden brought up the cost cap during his annual State of the Union address last month. He called for insulin costs for everyone to be capped at $35.
The state of California has said it plans to explore making its own cheaper insulin. Drugmakers also may face competition from companies like the nonprofit Civica, which plans to produce three insulins at a recommended price of no more than $30 a vial, a spokeswoman said.
Drugmakers may be seeing "the writing on the wall that high prices can't persist forever," said Larry Levitt, an executive vice president with the nonprofit Kaiser Family Foundation, which studies health care.
"Lilly is trying to get out ahead of the issue and look to the public like the good guy," Levitt said.
Indianapolis-based Eli Lilly and Co. became the first company to commercialize insulin in 1923, two years after University of Toronto scientists discovered it. The drugmaker then built its reputation around producing insulin even as it branched into cancer treatments, antipsychotics and other drugs.
Humulin and Humalog and its authorized generic brought in a total of more than $3 billion in revenue for Lilly last year. They rang up more than $3.5 billion the year before that.
"These are treatments that have had a really long and successful life and should be less costly to patients," Dusetzina said.
veryGood! (9)
Related
- Bill Belichick's salary at North Carolina: School releases football coach's contract details
- USA Gymnastics doesn't know who called Simone Biles a 'gold-medal token.' That's unacceptable.
- 4 arrested in twin newborn Amber Alert case in Michigan; many questions remain unanswered
- Schutz Seasonal Sale: Save Up to 60% On Ankle Boots, Lace-Up Boots & More Fall Must-Haves
- Paula Abdul settles lawsuit with former 'So You Think You Can Dance' co
- San Antonio shooter wounds 2 officers during car pursuit, police say
- Railroads resist joining safety hotline because they want to be able to discipline workers
- Taylor Swift Eras Tour Security Guard Says He Was Fired for Asking Fans to Take Pics of Him
- EU countries double down on a halt to Syrian asylum claims but will not yet send people back
- Extreme fire weather fueled by climate change played significant role in Canada's wildfires, new report says
Ranking
- Why Sean "Diddy" Combs Is Being Given a Laptop in Jail Amid Witness Intimidation Fears
- Heavy rains cause street flooding in the Detroit area, preventing access to Detroit airport terminal
- Starbucks’ Pumpkin Spice Latte turns 20: The famous fall beverage that almost wasn't
- Russia's General Armageddon reportedly dismissed after vanishing in wake of Wagner uprising
- A South Texas lawmaker’s 15
- Trump is set to turn himself in at Fulton County jail today. Here's what to know about his planned surrender.
- Zimbabwe’s election extends to a second day after long ballot delays. Some slept at polling stations
- Michigan teen’s death fueled anti-vaccine rhetoric. We got CDC’s investigative report.
Recommendation
Megan Fox's ex Brian Austin Green tells Machine Gun Kelly to 'grow up'
Paul Flores, Kristin Smart's killer, hospitalized after being attacked in prison, lawyer says
Flooding fills tunnels leading to Detroit airport, forces water rescues in Ohio and Las Vegas
ACC college football preview: Can Florida State knock off Clemson?
Former Danish minister for Greenland discusses Trump's push to acquire island
Heidi Klum denies rumor she eats 900 calories a day: 'Don't believe everything that you read'
CIA stairwell attack among flood of sexual misconduct complaints at spy agency
Maui County sues utility, alleging negligence over fires that ravaged Lahaina